ETFs with ALKS as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|2.62%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+6.90 (7.45%)|
|0.66%||N/A (SGGG)||N/A (N/A)|
|0%||QuantShares U.S. Market Neutral Size Fund ETF (SIZ)||+0.28 (1.12%)|
|0%||Schwab U.S. Small-Cap ETF (SCHA)||+6.55 (17.04%)|
|0%||Schwab U.S. Broad Market ETF (SCHB)||+5.72 (16.48%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. See "Forward-Looking Statements." Factors that might cause future results to differ materially from those projected in the forward-looking statements also include, but are not limited to, those discussed in "Item 1A—Risk Factors" and elsewhere in this Annual Report. On September 16, 2011, the business of Alkermes, Inc. ("Old Alkermes") and the drug technologies business ("EDT") of Elan Corporation, plc ("Elan") were combined (this combination is referred to as the "Business Combination," the "acquisition of EDT," or the "EDT acquisition") under Alkermes plc. As part of the Business Combination, Antler Acquisition Corp. ... More ...